Emma Kristin Johansson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emma Kristin Johansson has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Inger Kull
Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet Stockholm Sweden
5 shared publications - Natalia Ballardini
Institute of Environmental Medicine Karolinska Institutet Stockholm Sweden
5 shared publications Anna Bergström
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
3 shared publications- Anna Bergström
Institute of Environmental Medicine Karolinska Institutet Stockholm Sweden
2 shared publications Baltzar Bradley
Department of Dermatology, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden
2 shared publicationsCarl-Fredrik Wahlgren
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Dermatology, Karolinska University Hospital Solna, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 11 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1306-1309.e4
Baricitinib Blocks Cytokine-Mediated Downregulation of PAD1 in Human Keratinocytes: A Possible Molecular Link to the Effects of JAK Inhibitors in Atopic Dermatitis
- 11 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1306-1309.e4
Open AccessBaricitinib Blocks Cytokine-Mediated Downregulation of PAD1 in Human Keratinocytes: A Possible Molecular Link to the Effects of JAK Inhibitors in Atopic Dermatitis
- Open Access
- 11 June 2021
- Published by Wiley in British Journal of Dermatology
- Vol. 185 (1) , 8-9
Psychiatric conditions in children with atopic dermatitis
- 11 June 2021
- Published by Wiley in British Journal of Dermatology
- Vol. 185 (1) , 8-9
Open AccessPsychiatric conditions in children with atopic dermatitis
- Open Access
- 12 March 2021
- Published by SAGE Publications in International Review for the Sociology of Sport
- Vol. 57 (1) , 54-72
A gang of ironworkers with the scent of blood: A participation observation of male dominance and its historical trajectories at Swedish semi-professional ice hockey events
Ice hockey has traditionally been a male-dominated culture that has both promoted and legitimised masculine dominance and gender inequality. The question is, how might ice hockey games, or other male-dominated sports, be organised differently and thus become more gender equal? Our ambition in this article is to initiate a discussion about how the construction of gender in ice hockey events operationalises or opposes the dominance of men and the marginalisation of women. The specific purpose is to identify techniques that configure men/masculinities as dominant in the ice hockey culture. Taking critical studies of men and masculinities as the point of departure, with a specific focus on the situational aspects of gender construction, this case study makes use of participatory observations of eight qualification games in Swedish semi-professional ice hockey. Our results show that men and certain types of masculinity dominate in the events framing the game and how this links the ice hockey players and the club with the local body-worker culture and its industrial, economic and historical context. Identification with these men is ideally created amongst male spectators, given that children and women do not have the same obvious place in the event’s narrative. Some clubs seek to include women and children in their matches, which affects both the atmosphere and the situation. By focusing on the events’ introductions and general narratives, and how they make use of a (masculine) version of the place’s past in the present, we discuss how the ice hockey culture contributes to the current hegemony of men and masculinities.
- 12 March 2021
- Published by SAGE Publications in International Review for the Sociology of Sport
- Vol. 57 (1) , 54-72
Open AccessA gang of ironworkers with the scent of blood: A participation observation of male dominance and its historical trajectories at Swedish semi-professional ice hockey events
Ice hockey has traditionally been a male-dominated culture that has both promoted and legitimised masculine dominance and gender inequality. The question is, how might ice hockey games, or other male-dominated sports, be organised differently and thus become more gender equal? Our ambition in this article is to initiate a discussion about how the construction of gender in ice hockey events operationalises or opposes the dominance of men and the marginalisation of women. The specific purpose is to identify techniques that configure men/masculinities as dominant in the ice hockey culture. Taking critical studies of men and masculinities as the point of departure, with a specific focus on the situational aspects of gender construction, this case study makes use of participatory observations of eight qualification games in Swedish semi-professional ice hockey. Our results show that men and certain types of masculinity dominate in the events framing the game and how this links the ice hockey players and the club with the local body-worker culture and its industrial, economic and historical context. Identification with these men is ideally created amongst male spectators, given that children and women do not have the same obvious place in the event’s narrative. Some clubs seek to include women and children in their matches, which affects both the atmosphere and the situation. By focusing on the events’ introductions and general narratives, and how they make use of a (masculine) version of the place’s past in the present, we discuss how the ice hockey culture contributes to the current hegemony of men and masculinities.
- Open Access
- 22 September 2020
- Published by Springer Nature in BMC Dermatology
- Vol. 20 (1) , 1-7
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
Background: Dupilumab, targeting the interleukin-4α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data on long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain was observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in a cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after 12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or disturbed night sleep due to itching.Methods: All patients with atopic dermatitis receiving systemic treatment at the Unit of Dermatology, Karolinska University Hospital, have been registered and monitored consecutively since January 2017. This cohort constituted all patients who started treatment on dupilumab or methotrexate between 10 January 2017 and 30 June 2019 with at least 6 months of follow-up within the study period. The following variables were monitored at start of and during treatment: Eczema Severity Score Index, Patient-Oriented Eczema Measure, visual analogue scale for pruritus 10 cm, Montgomery-Åsberg Depression Rating Scale, Dermatology Life Quality Index, and weight. Data analyses were performed using two-sample Wilcoxon-Mann-Whitney rank-sum test, or the Wilcoxon matched-pairs sign-rank test with ap-value < 0.05 considered as statistically significant.Results: Patients treated with dupilumab (n = 12) gained weight (mean 6.1 kg, range [0.1–18.0],p = 0.002) after 1 year on treatment. The majority of patients showed a good response to treatment with dupilumab (n = 11); at follow-up at 6, 9, or 12 months, they reached EASI-90 (n = 6), EASI-75 (n = 4), or EASI-50 (n = 1). There was no significant association between weight gain and treatment response, reported appetite, or disturbed night-sleep due to itch. Patients treated with methotrexate showed no significant weight change (n = 8).Conclusions: To our knowledge, this is the first report on a possible association between weight gain and dupilumab treatment; the extent of the association is yet to be seen, as is the mechanism behind this finding.
- 22 September 2020
- Published by Springer Nature in BMC Dermatology
- Vol. 20 (1) , 1-7
Open AccessWeight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
Background: Dupilumab, targeting the interleukin-4α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data on long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain was observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in a cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after 12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or disturbed night sleep due to itching.Methods: All patients with atopic dermatitis receiving systemic treatment at the Unit of Dermatology, Karolinska University Hospital, have been registered and monitored consecutively since January 2017. This cohort constituted all patients who started treatment on dupilumab or methotrexate between 10 January 2017 and 30 June 2019 with at least 6 months of follow-up within the study period. The following variables were monitored at start of and during treatment: Eczema Severity Score Index, Patient-Oriented Eczema Measure, visual analogue scale for pruritus 10 cm, Montgomery-Åsberg Depression Rating Scale, Dermatology Life Quality Index, and weight. Data analyses were performed using two-sample Wilcoxon-Mann-Whitney rank-sum test, or the Wilcoxon matched-pairs sign-rank test with ap-value < 0.05 considered as statistically significant.Results: Patients treated with dupilumab (n = 12) gained weight (mean 6.1 kg, range [0.1–18.0],p = 0.002) after 1 year on treatment. The majority of patients showed a good response to treatment with dupilumab (n = 11); at follow-up at 6, 9, or 12 months, they reached EASI-90 (n = 6), EASI-75 (n = 4), or EASI-50 (n = 1). There was no significant association between weight gain and treatment response, reported appetite, or disturbed night-sleep due to itch. Patients treated with methotrexate showed no significant weight change (n = 8).Conclusions: To our knowledge, this is the first report on a possible association between weight gain and dupilumab treatment; the extent of the association is yet to be seen, as is the mechanism behind this finding.
- Open Access
- 16 September 2020
- Published by Springer Nature in Research Square
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
Background Dupilumab, targeting the interleukin-4α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data on long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain was observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in a cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after 12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or disturbed night sleep due to itching.Methods All patients with atopic dermatitis receiving systemic treatment at the Unit of Dermatology, Karolinska University Hospital, have been registered and monitored consecutively since January 2017. This cohort constituted all patients who started treatment on dupilumab or methotrexate between 10 January 2017 and 30 June 2019 with at least 6 months of follow-up within the study period. The following variables were monitored at start of and during treatment: Eczema Severity Score Index, Patient-Oriented Eczema Measure, visual analogue scale for pruritus 10cm, Montgomery-Åsberg Depression Rating Scale, Dermatology Life Quality Index, and weight. Data analyses were performed using two-sample Wilcoxon-Mann-Whitney rank-sum test, or the Wilcoxon matched-pairs sign-rank test with a p-value Results Patients treated with dupilumab (n=12) gained weight (mean 6.1 kg, range [0.1–18.0], p=0.002) after one year on treatment. The majority of patients showed a good response to treatment with dupilumab (n=11); at follow-up at 6, 9, or 12 months, they reached EASI-90 (n=6), EASI-75 (n=4), or EASI-50 (n=1). There was no significant association between weight gain and treatment response, reported appetite, or disturbed night-sleep due to itch. Patients treated with methotrexate showed no significant weight change (n=8). Conclusions To our knowledge, this is the first report on a possible association between weight gain and dupilumab treatment; the extent of the association is yet to be seen, as is the mechanism behind this finding.
- 16 September 2020
- Published by Springer Nature in Research Square
Open AccessWeight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
Background Dupilumab, targeting the interleukin-4α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data on long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain was observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in a cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after 12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or disturbed night sleep due to itching.Methods All patients with atopic dermatitis receiving systemic treatment at the Unit of Dermatology, Karolinska University Hospital, have been registered and monitored consecutively since January 2017. This cohort constituted all patients who started treatment on dupilumab or methotrexate between 10 January 2017 and 30 June 2019 with at least 6 months of follow-up within the study period. The following variables were monitored at start of and during treatment: Eczema Severity Score Index, Patient-Oriented Eczema Measure, visual analogue scale for pruritus 10cm, Montgomery-Åsberg Depression Rating Scale, Dermatology Life Quality Index, and weight. Data analyses were performed using two-sample Wilcoxon-Mann-Whitney rank-sum test, or the Wilcoxon matched-pairs sign-rank test with a p-value Results Patients treated with dupilumab (n=12) gained weight (mean 6.1 kg, range [0.1–18.0], p=0.002) after one year on treatment. The majority of patients showed a good response to treatment with dupilumab (n=11); at follow-up at 6, 9, or 12 months, they reached EASI-90 (n=6), EASI-75 (n=4), or EASI-50 (n=1). There was no significant association between weight gain and treatment response, reported appetite, or disturbed night-sleep due to itch. Patients treated with methotrexate showed no significant weight change (n=8). Conclusions To our knowledge, this is the first report on a possible association between weight gain and dupilumab treatment; the extent of the association is yet to be seen, as is the mechanism behind this finding.
- 8 March 2019
- Published by Wiley in Acta Paediatrica
- Vol. 108 (6) , 1023-1027
Paediatric haematohidrosis: an overview of a rare but clinically distinct condition
Haematohidrosis is a rare and dramatic condition in which bleeding occurs spontaneously from intact skin. We report the case of a nine‐year‐old boy with a typical clinical presentation. The case highlights how challenging it can be for medical professionals to recognise and evaluate rare conditions. A review of the literature was performed, showing that haematohidrosis is mainly a paediatric condition. Our case together with findings from the review indicates that treatment with Beta blockers may be effective for treatment of haematohidrosis in children.Conclusion: Paediatric haematohidrosis is a rare, but clinically distinct condition. Treatment with Beta blockers may be tested.
- 8 March 2019
- Published by Wiley in Acta Paediatrica
- Vol. 108 (6) , 1023-1027
Paediatric haematohidrosis: an overview of a rare but clinically distinct condition
Haematohidrosis is a rare and dramatic condition in which bleeding occurs spontaneously from intact skin. We report the case of a nine‐year‐old boy with a typical clinical presentation. The case highlights how challenging it can be for medical professionals to recognise and evaluate rare conditions. A review of the literature was performed, showing that haematohidrosis is mainly a paediatric condition. Our case together with findings from the review indicates that treatment with Beta blockers may be effective for treatment of haematohidrosis in children.Conclusion: Paediatric haematohidrosis is a rare, but clinically distinct condition. Treatment with Beta blockers may be tested.
- Open Access
- 12 November 2018
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 11 (3) , 751-755
Severe Photo Toxicity Recalled by Docetaxel
Photo-recall phenomenon is a rarely recognized adverse event of chemotherapeutic agents. The physiopathology of this entity is unclear. We have reported a 56-year old breast cancer patient with severe photo toxicity recalled 5 months after the initial sunburn by one course of adjuvant docetaxel treatment. However, being given right diagnosis and proper managements the patient could be able to complete her adjuvant chemotherapy according to the planed time schedule, without any delay. Our case may be explained by the theory that long-lived memory T-cells may remember former skin damage and cross-react with cytotoxic drugs. In addition, we have proved that weekly paclitaxel can still be the drug of option after docetaxel recalled severe photo toxicity.
- 12 November 2018
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 11 (3) , 751-755
Open AccessSevere Photo Toxicity Recalled by Docetaxel
Photo-recall phenomenon is a rarely recognized adverse event of chemotherapeutic agents. The physiopathology of this entity is unclear. We have reported a 56-year old breast cancer patient with severe photo toxicity recalled 5 months after the initial sunburn by one course of adjuvant docetaxel treatment. However, being given right diagnosis and proper managements the patient could be able to complete her adjuvant chemotherapy according to the planed time schedule, without any delay. Our case may be explained by the theory that long-lived memory T-cells may remember former skin damage and cross-react with cytotoxic drugs. In addition, we have proved that weekly paclitaxel can still be the drug of option after docetaxel recalled severe photo toxicity.
- Open Access
- 17 September 2018
- Published by Wiley in British Journal of Dermatology
- Vol. 179 (3) , e141
Emollients and topical glucocorticoids in adolescents with eczema
- 17 September 2018
- Published by Wiley in British Journal of Dermatology
- Vol. 179 (3) , e141
Open AccessEmollients and topical glucocorticoids in adolescents with eczema
- Open Access
- 1 July 2018
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 98 (7) , 630-635
Prognosis of Preschool Eczema and Factors of Importance for Remission
Information on factors of importance for remission of eczema is scarce. This study explored factors ...
- 1 July 2018
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 98 (7) , 630-635
Open AccessPrognosis of Preschool Eczema and Factors of Importance for Remission
Information on factors of importance for remission of eczema is scarce. This study explored factors ...
- 25 February 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (3) , 709-716
Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE
Background Knowledge regarding how adolescents treat their eczema is sparse. Objectives To explore the use of emollients and topical glucocorticoids in adolescents with eczema in relation to sex and disease severity, and to study dispensing patterns of topical glucocorticoids. Methods Questionnaire-based data on symptoms of eczema, eczema severity and treatment with emollients and topical glucocorticoids were obtained from 3108 adolescents in the Swedish population-based birth cohort BAMSE. Severity of reported eczema was evaluated with the BAMSE Eczema Severity Score (BESS) in a questionnaire and with the Patient-Oriented Eczema Measure in clinically examined patients with current eczema (n = 247). Information on dispensed topical glucocorticoids was obtained from the Swedish Prescribed Drug Register. Results In all, 10% of the adolescents reported eczema in the preceding year: 73% mild, 17% moderate and 10% severe according to BESS. Almost all used emollients, whereas use of topical glucocorticoids was reported by 55%, with no significant difference between sexes. The likelihood of treatment with emollients and topical glucocorticoids increased when the adolescents had symptoms of current eczema [adjusted odds ratio (OR) 5·95, 95% confidence interval (CI) 1·90–18·8], but not if they had more severe eczema compared with mild eczema (adjusted OR 1·57, 95% CI 0·58–4·25). Among those with reported eczema, 24% had a topical glucocorticoid dispensed in the preceding year, and among those with moderate-to-severe current eczema 24% had a dispensed potent topical glucocorticoid. Conclusions This population-based study indicates that adolescents with eczema are undertreated or completely untreated, even those with severe eczema.
- 25 February 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (3) , 709-716
Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE
Background Knowledge regarding how adolescents treat their eczema is sparse. Objectives To explore the use of emollients and topical glucocorticoids in adolescents with eczema in relation to sex and disease severity, and to study dispensing patterns of topical glucocorticoids. Methods Questionnaire-based data on symptoms of eczema, eczema severity and treatment with emollients and topical glucocorticoids were obtained from 3108 adolescents in the Swedish population-based birth cohort BAMSE. Severity of reported eczema was evaluated with the BAMSE Eczema Severity Score (BESS) in a questionnaire and with the Patient-Oriented Eczema Measure in clinically examined patients with current eczema (n = 247). Information on dispensed topical glucocorticoids was obtained from the Swedish Prescribed Drug Register. Results In all, 10% of the adolescents reported eczema in the preceding year: 73% mild, 17% moderate and 10% severe according to BESS. Almost all used emollients, whereas use of topical glucocorticoids was reported by 55%, with no significant difference between sexes. The likelihood of treatment with emollients and topical glucocorticoids increased when the adolescents had symptoms of current eczema [adjusted odds ratio (OR) 5·95, 95% confidence interval (CI) 1·90–18·8], but not if they had more severe eczema compared with mild eczema (adjusted OR 1·57, 95% CI 0·58–4·25). Among those with reported eczema, 24% had a topical glucocorticoid dispensed in the preceding year, and among those with moderate-to-severe current eczema 24% had a dispensed potent topical glucocorticoid. Conclusions This population-based study indicates that adolescents with eczema are undertreated or completely untreated, even those with severe eczema.